Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSe Trial

被引:11
作者
Moro-Sibilot, D. [1 ]
Cozic, N. [2 ]
Perol, M. [3 ]
Otto, J. [4 ]
Mazieres, J. [5 ]
Souquet, P. [6 ]
Bahleda, R. [2 ]
Wislez, M. [7 ]
De Guibert, S. [8 ]
Mennecier, B. [9 ]
Chouaid, C. [10 ]
Sabatier, R. [11 ]
Bota, S. [12 ]
Gervais, R. [13 ]
Verriele, V. [14 ]
Haddad, V. [3 ]
Ferretti, G. [1 ]
Nowak, F. [15 ]
Oukhatar, C. Mahier-Ait [16 ]
Vassal, G. [2 ]
机构
[1] Hop Michallon, CHU Grenoble, Grenoble, France
[2] Gustave Roussy Canc Campus Grand Paris, Villejuif, France
[3] Ctr Leon Berard, Lyon, France
[4] Ctr Antoine Lacassagne, Nice, France
[5] Hop Larrey, CHU Toulouse, Toulouse, France
[6] Hop Lyon Sud, Ctr Hosp, Pierre Benite, France
[7] Hop Univ Est Parisien, Hop Tenon, Paris, France
[8] Hop Pontchaillou, CHR, Rennes, France
[9] Hop Civil, Ctr Hosp Strasbourg, Strasbourg, France
[10] Ctr Hosp Intercommunal Creteil, Creteil, France
[11] lnst Paoli Calmettes, Marseille, France
[12] Hop Charles Nicolle, CHU Rouen, Rouen, France
[13] Ctr Francois Baclesse, Caen, France
[14] lnst Cancerol Louest Paul Papin, Angers, France
[15] Inst Natl Canc, Boulogne Billancourt, France
[16] Unicanc, Paris, France
关键词
crizotinib; NSCLC; MET or ROS1 alterations;
D O I
10.1016/j.jtho.2018.08.301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OA12.03
引用
收藏
页码:S348 / S348
页数:1
相关论文
empty
未找到相关数据